|
The following stocks are the leading risers and fallers on AIM on Thursday. ---------- AIM - WINNERS ---------- Arecor Therapeutics PLC, up 21% at 87.94 pence, 12-month range 35.40p-100.00p. The Cambridgeshire, England-based biopharmaceutical company reports pretax loss of £2.5 million for the six months that ended June 30, narrowed from £4.8 million the year before. Revenue rises 0.4% to £2.0 million, while sales, general and administrative expenses reduce by 38% to £2.1 million from £3.4 million. Research and development expenses are down 24% to £1.3 million from £1.7 million. Arecor also records a one-off £409,000 gain on the disposal of non-Ogluo Tetris Pharma products. ‘During 1H 2025, we advanced partner discussions around both AT278 and our financial position, culminating in the two partnership agreements announced today,’ says Chief Executive Officer Sarah Howell. ‘The co-development agreement with Sequel, our US pump partner, will accelerate AT278’s progress towards a pivotal Phase 2 clinical study. The royalty financing agreement with Ligand enables us to immediately co-fund trial-enabling development activities for the AT278 programme, as well as strengthening the balance sheet with a cash runway into 1H 2027. We enter 2H 2025 from a position of strength as we prepare AT278 for Phase 2 studies in 2026 and continue to drive research into our oral peptide delivery platform.’ ---------- AIM - LOSERS ---------- Proteome Sciences PLC, down 37% at 2.00p, 12-month range 1.65p-5.40p. The London-based protein-focused drug development services provider posts a pretax loss of £2.07 million for the six months to June 30, narrowed from £2.15 million the year before. Revenue reduces by 14% to £1.9 million from £2.2 million, as services revenue nearly triples to £1.1 million from £370,000 while TMTpro sales fall 72% to £380,000 from £1.4 million. Cost of sales is down 25% to £1.5 million from £2.0 million. Chair Christopher Pearce says: ‘The dramatic upheaval in world trade arising from US policy on tariffs, and the substantial parallel cuts to the [National Institute of Health] budget and academic research funding have inevitably had a negative impact on all businesses working in life sciences...Despite the headwinds and after considerable increases in customer orders, demand for our services business rebounded strongly and we remain optimistic that we are well positioned to deliver future increases in revenue and returns.’ ---------- Bradda Head Lithium Ltd, down 29% at 1.01p, 12-month range 0.85p-1.50p. The North American-focused lithium explorer and owner of the Basin project in Arizona enters a short-term $500,000 loan facility with Galloway Ltd. Funds will ‘provide support for the company to maintain its good standing and will be used for general working capital purposes’, the company says. The facility is unsecured, with a one-year availability and repayment term, and a 12% annual interest rate. Bradda will accelerate its repayment if it completes an equity fundraising during the term of the loan. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
